ArticleDiscover oncology2025
Evaluating the survival benefit of adjuvant chemotherapy based on tumor deposit status in stage II colon cancer patients from SEER database.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveColon cancer is a common malignancy with a high mortality rate. The staging of tumor deposits (TD) in colon cancer prognosis has been a subject of controversy. The aim of this study was to evaluate the impact of adjuvant chemotherapy (ACT) on overall survival (OS) and cancer-specific survival (CSS) in stage II colon cancer patients, with a specific focus on whether TD status modifies the treatment effect and to validate the AJCC 8th edition criteria for TD staging.
methodWe identified eligible patients with stage II colon cancer (N = 21,499) from the SEER database, covering the period from January 2000 to December 2018. We used subgroup analysis to explore the relationship between chemotherapy and tumor deposits, and a forest plot was drawn. A 1:1 Propensity Score Matching (PSM) was utilized to create a matched cohort with balanced baseline characteristics, reducing bias.
resultAfter PSM, ACT demonstrated significant OS benefits in both the overall population (HR, 0.87; P = 0.01) and the TD-free subgroup (HR, 0.88; P = 0.018), while the negative association with CSS was no longer significant (HR, 1.13; P = 0.079), indicating effective bias control. Interaction analyses confirmed statistically comparable treatment effects of ACT irrespective of TD status for both OS and CSS. Multivariate analysis identified ACT as an independent prognostic factor for improved OS, while tumor deposits were a significant independent adverse prognostic factor for both CSS and OS (all P < 0.001).
conclusionThis study confirms that tumor deposits is an independent and significant prognostic factor for colorectal cancer patients and provides some evidence for the accuracy of the AJCC 8th edition in classifying the presence of tumor deposits as N1c.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.